Cybin announces grant of additional u.s. patent in support of its cyb003 breakthrough therapy program for major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the united states patent and trademark office has granted u.s. patent 11,958,807 in support of its cyb003 program in major depressive disorder (“mdd”). the patent, which is expected to provide exclusiv.
CYBN Ratings Summary
CYBN Quant Ranking